Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 29, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share repurchase activity.
- Shares Purchased: 550,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,369.8091 pence per share.
- Treasury Shares Held: 227,319,678 shares (post-transaction).
- Shares in Issue: 5,762,303,850 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on November 29, 2006. This transaction was conducted under authority granted by shareholders at the Annual General Meeting on May 17, 2006. The acquired shares are intended to be held in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 550,000 share repurchase based on the stated price of 1,369.8091 pence.
- Confirm the updated total share count (5,762,303,850 in issue) against subsequent filings.
- Review the May 17, 2006 Annual General Meeting minutes to confirm the scope of the share buyback authority utilized.
- Check for any subsequent filings regarding the retirement or re-issuance of the 227,319,678 Treasury shares.